摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

麦芽糖醇 | 585-88-6

中文名称
麦芽糖醇
中文别名
4-O-alpha-吡喃葡萄糖基-D-山梨糖醇;4-O-α-吡喃葡萄糖基-D-山梨糖醇;4-O-2-D-乙二醇吡喃山絮糖醇;氫化麥芽糖
英文名称
MALTITOL
英文别名
(2S,3R,4R,5R)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,5,6-pentol
麦芽糖醇化学式
CAS
585-88-6
化学式
C12H24O11
mdl
MFCD00006600
分子量
344.316
InChiKey
VQHSOMBJVWLPSR-WUJBLJFYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    149-152 °C (lit.)
  • 比旋光度:
    [α]D20 +106~+108゜ (c=0.8, H2O)
  • 沸点:
    399.42°C (rough estimate)
  • 密度:
    1.3863 (rough estimate)
  • 溶解度:
    极易溶于水,几乎不溶于无水乙醇。
  • LogP:
    -3.87 at 24℃
  • 物理描述:
    DryPowder; Liquid
  • 颜色/状态:
    White powder
  • 气味:
    Neutral
  • 味道:
    Sweet
  • 蒸汽压力:
    4.82X10-16 mm Hg at 25 °C (est)
  • 稳定性/保质期:
    由于吸湿性很强,一般商品通常含有70%麦芽糖醇的水溶液。这种水溶液是无色透明、中性的粘稠液体,甜度约为蔗糖的85%-95%。它难以发酵,并具有非结晶性、保香和保湿作用。在pH值3-9范围内耐热,加热不易分解。与蛋白质或氨基酸共存时加热,通常不会发生反应。在人体内无法被消化吸收,除了肠内细菌可利用一部分外,其余部分均无法消化而排出体外。其热量极低,发热量仅为1.67kJ/kg,相当于蔗糖的十分之一。
  • 旋光度:
    Specific optical rotation: +106.5 deg at 20 °C/D
  • 分解:
    When /maltitol/ is heated at temperatures above 200 °C, decomposition begins (depending on time, temperature, adn other prevailing conditions). Maltitol does not undergo browning reactions with amino acids, and absorbs atmospheric moisture only at relative humidities of 89% and above, at 20 °C.

计算性质

  • 辛醇/水分配系数(LogP):
    -5.2
  • 重原子数:
    23
  • 可旋转键数:
    8
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    201
  • 氢给体数:
    9
  • 氢受体数:
    11

ADMET

代谢
麦芽糖醇(4-α-D-葡萄糖基山梨醇)的代谢在禁食常规(C)大鼠、C小鼠和无菌(GF)小鼠中进行评估,使用[U-14C]麦芽糖醇。在给予标记麦芽糖醇后48小时内收集的(14)CO2的放射性呼吸模式表现为C大鼠和小鼠在持续4小时内的(14)CO2产生速率恒定。GF小鼠的模式在第二小时出现峰值,随后立即缓慢下降。GF小鼠的(14)CO2回收百分比(59%)显著低于C动物(72-74%)。48小时后,C大鼠和小鼠的尿液、粪便和肠内容物总计占给药放射活性的19%,GF小鼠为39%。还评估了GF小鼠对麦芽糖醇的消化性和山梨醇的吸收。GF小鼠在给予等摩尔量的麦芽糖醇(140 mg/kg体重)或山梨醇(70 mg/kg体重)3小时后,盲肠和小肠分别含有摄入剂量的39%和51%,大部分以山梨醇的形式存在于盲肠中。GF小鼠的小肠的α-葡萄糖苷酶(麦芽糖酶)活性显著高于C小鼠(1.5-1.7倍)。这些结果表明,小鼠和大鼠小肠中的酶活性足以广泛水解麦芽糖醇。因此,山梨醇的缓慢吸收似乎是限制麦芽糖醇在小肠中整体吸收的重要因素。
The metabolism of maltitol (4-alpha-D-glucosylsorbitol) was assessed in fasting conventional (C) rats, C mice and germ-free (GF) mice, using [U-14C]maltitol. The radiorespirometric patterns of (14)CO2 collected for 48 hr after the administration of labelled maltitol were characterized by a constant rate of (14)CO2 production lasting 4 hr for both C rats and mice. The pattern for the GF mice showed a peak at the second hour followed immediately by a slow decrease. The percentage recovery of (14)CO2 was significantly lower for the GF mice (59%) compared with C animals (72-74%). Urine, feces and intestinal contents after 48 hr totalled 19% of the administered radioactivity in the C rats and mice and 39% in the GF mice. The digestibility of maltitol and the absorption of sorbitol in GF mice was also assessed. The cecum and small intestine of GF mice, 3 hr after administration of equimolar quantities of maltitol (140 mg/kg body-weight) or sorbitol (70 mg/kg body-weight), contained 39 and 51% of the ingested dose respectively, present mostly in the cecum as sorbitol. The alpha-glucosidase (maltase) activity of the small intestine was appreciably higher (1.5-1.7 times) in the GF mice than in the C mice. These results suggest that the enzymic activities in the small intestine of mice and rats are sufficient to hydrolyse maltitol extensively. Consequently, the slow absorption of sorbitol seems to be an important factor limiting the overall assimilation of maltitol in the small intestine.
来源:Hazardous Substances Data Bank (HSDB)
代谢
常规(CV)大鼠单次口服1或2克麦芽糖醇。在接下来的24小时内收集尿液和粪便,并测量其中的麦芽糖醇和山梨糖醇含量。这两种物质在粪便中的出现量非常少,但在尿液中发现的山梨糖醇的量表明麦芽糖醇已被水解。在无菌和CV大鼠中比较了口服2克麦芽糖醇后麦芽糖醇和山梨糖醇的排泄情况。在CV大鼠的粪便中回收的这两种物质显著较少,但尿液排泄在两种环境中相似。静脉注射麦芽糖醇仅在排泄物中产生少量山梨糖醇。250毫克的剂量在1小时内几乎完全从循环中清除。因此,麦芽糖醇被动物组织水解,无论是在吸收前的肠道腔内还是在吸收过程中的肠道壁上。麦芽糖醇和山梨糖醇也被肠道细菌降解,主要在远离主要吸收区域的地方。对宿主营养的贡献将取决于发酵终产品从结肠被吸收的程度。
Conventional (CV) rats were given a single oral dose of 1 or 2 g maltitol. Urine and faeces were collected during the following 24 hr and their contents of maltitol and sorbitol were measured. Very little of either substance appeared in the faeces but appreciable amounts of sorbitol found in the urine indicated that the maltitol had been hydrolysed. Excretion of maltitol and sorbitol was compared in germ-free and CV rats given an oral dose of 2 g maltitol. Significantly less of both substances was recovered in the faeces of CV rats, but urinary excretion was similar in both environments. Maltitol injected intravenously gave rise to only traces of sorbitol in the excreta. A dose of 250 mg was cleared almost completely from the circulation within 1 hr. It is concluded that maltitol is hydrolysed by animal tissues, either in the gut lumen before absorption or in the gut wall during absorption. Maltitol and sorbitol are also degraded by gut bacteria, mostly in sites distal to the main absorptive area. The contribution to the host's nutrition would depend on the extent to which the end-products of fermentation are absorbed from the colon.
来源:Hazardous Substances Data Bank (HSDB)
代谢
13%或26%麦芽糖醇的饮食喂养9周后,Wistar大鼠的体重增长降低,肠道重量增加,与对照组相比。在给药大鼠的酶学测试中表明,麦芽糖醇的α-糖苷键没有被胰腺酶或肠道粘膜酶水解。在肝细胞质中未观察到麦芽糖醇脱氢酶,且长期给予麦芽糖醇并未诱导肝脏山梨糖醇脱氢酶。
Weanling Wistar rats placed on diets containing 13 or 26% maltitol for 9 weeks had reduced body-weight gains and increased intestinal weights as compared with controls. Enzymatic tests in dosed rats indicated that the alpha-glycosidic linkage of maltitol was not hydrolysed with pancreatic enzymes or enzymes of the intestinal mucosa. Maltitol dehydrogenase was not observed in liver-cell cytoplasm and prolonged maltitol administration did not induce hepatic sorbitol dehydrogenase.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
麦芽糖醇和甘露醇对小鼠胃肠道吸收对乙酰氨基酚、磺胺异噁唑和核黄素的影响在控制的双盲条件下进行了研究。口服麦芽糖醇或甘露醇给6只小鼠,摄入后2小时发现这3种药物的血液水平低于对照组,药物吸收受到抑制。结果表明,这些结果是由麦芽糖醇和甘露醇的作用引起的,它们加速了小肠的运动、分泌和肠膜血管的通透性。这些变化可能由小肠中的生物胺、血清素、组胺和聚胺介导。
The effects of maltitol and mannitol on the /gastrointestinal/ absorption of acetaminophen, sulfisoxazole and riboflavin in mice were investigated in a controlled double-blind fashion. Oral maltitol or mannitol was administered to 6 mice and 2 hr after ingestion the blood levels of the 3 drugs were found to be lower than in the controls, and drug absorption was inhibited. It was suggested that these results were caused by the action of maltitol and mannitol which accelerated small intestine motility, secretion and vascular permeability in the intestinal membrane. These changes may be mediated by biogenic amine, serotonin, histamine and polyamines in the small intestine.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
为了估计部分水解瓜尔胶(PHGG)对女性受试者因摄入足量麦芽糖醇或乳糖醇而引发的暂时性腹泻的抑制效果。首先,分别估算每个受试者引发暂时性腹泻的麦芽糖醇和乳糖醇的最小剂量水平。每个受试者按步骤增加5克,从10克到45克,直到出现腹泻。此后,观察在受试者摄入5克PHGG和最小剂量水平的麦芽糖醇或乳糖醇混合物后,对腹泻的抑制效果。共有34名正常女性受试者(年龄21.3±0.9岁;体重49.5±5.3公斤)。记录因摄入麦芽糖醇或乳糖醇引起的腹泻发生率以及通过添加PHGG实现的抑制比率。 摄入最多45克麦芽糖醇时,34名受试者中有29名(85.3%)出现腹泻,而摄入乳糖醇则导致100%的受试者出现腹泻。在麦芽糖醇引起的腹泻中,有28名受试者中的10名通过向最小剂量引发的腹泻中添加5克PHGG得到改善,而乳糖醇引起的腹泻中有19名受试者中的7名得到改善。添加10克PHGG强烈抑制了由麦芽糖醇引起的腹泻,累积抑制比率为82.1%(23/28)。由摄入麦芽糖醇或乳糖醇引起的暂时性腹泻通过添加PHGG得到了明显抑制。这些结果强烈表明,由摄入足量非消化糖替代品引起的腹泻可以通过添加膳食纤维得到抑制。
To estimate the suppressive effect of partially hydrolyzed guar gum (PHGG) on transitory diarrhea induced by ingestion of a sufficient amount of maltitol or lactitol in female subjects. The first, the minimal dose level of maltitol and lactitol that would induce transitory diarrhea was estimated separately for each subject. Individual subject was administered a dose that increased by 5 g stepwise from 10 to 45 g until diarrhea was experienced. Thereafter, the suppressive effect on diarrhea was observed after each subject ingested a mixture of 5 g of PHGG and the minimal dose level of maltitol or lactitol. Thirty-four normal female subjects (21.3+/-0.9 years; 49.5+/-5.3 kg). Incidence of diarrhea caused by the ingestion of maltitol or lactitol and the ratio of suppression achieved by adding PHGG for diarrhea. The ingestion of amounts up to 45 g of maltitol, diarrhea caused in 29 of 34 subjects (85.3%), whereas the ingestion of lactitol caused diarrhea in 100%. The diarrhea owing to maltitol was improved in 10 of 28 subjects by the addition of 5 g of PHGG to minimal dose-induced diarrhea, and that owing to lactitol was in seven of 19 subjects. Adding 10 g of PHGG strongly suppressed the diarrhea caused by maltitol, and the cumulative ratio was 82.1% (23/28). The transitory diarrhea caused by the ingestion of maltitol or lactitol was clearly suppressed by the addition of PHGG. These results strongly suggest that diarrhea caused by the ingestion of a sufficient amount of non-digestible sugar substitute can be suppressed by the addition of dietary fiber.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
麦芽糖醇(alpha-D-葡萄糖苷-1,4-山梨醇)对大鼠肠道吸收钙的增强效果已经通过使用[(45)Ca]CaCl2进行了体内研究。在胃内给予含有麦芽糖醇的[(45)Ca]CaCl2溶液后,血浆中(45)Ca的浓度在80分钟以上保持在最高水平,而对于只给予不含麦芽糖醇的[(45)Ca]CaCl2溶液的动物,血浆中(45)Ca的浓度在峰值后迅速下降。测定胃肠道各段中剩余的(45)Ca放射性活性,发现给予麦芽糖醇后,胃排空和肠传输速度减慢,导致在整个实验期间(45)Ca在小肠中广泛分布。给予麦芽糖醇的大鼠的小肠腔内容物显著高于对照组。这些结果表明,麦芽糖醇对肠道钙吸收的增强作用可能是由于减少了胃肠道钙的传输速度和增加了腔内液体的含量,这可能是由于麦芽糖醇的渗透活性;这不仅加速了钙溶解到增加的腔内容物中,而且使得更大的小肠面积能够在更长的时间内吸收钙。
The enhancing effects of maltitol (alpha-D-glucopyranosyl-1,4-sorbitol) on absorption of calcium by the rat intestine have been studied by use of [(45)Ca]CaCl2 in-vivo. After intragastric administration of [(45)Ca]CaCl2 solution with maltitol, plasma (45)Ca concentration remained at the maximum level for more than 80 min, whereas for animals given [(45)Ca]CaCl2 solution without maltitol, plasma (45)Ca concentration declined sharply after the peak. Determination of (45)Ca radioactivity remaining in the various segments of the gastrointestinal tract revealed that administration of maltitol elicited slower gastric emptying and slower intestinal transit, resulting in extensive (45)Ca distribution along the small intestine throughout the experimental period. The luminal contents of the small intestine were significantly higher in rats given maltitol than in the control group. These results suggest that the enhancing action of maltitol on intestinal calcium absorption could be attributed to reduced gastrointestinal calcium transit and increased luminal fluid content, presumably because of the osmotic activity of maltitol; this would not only accelerate the dissolution of calcium into the increased luminal contents, but also enable a larger area of the small intestine to absorb calcium for a longer period of time.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 相互作用
龋齿和牙周病是普遍存在的口腔疾病,其病因与碳水化合物甜味剂的摄入密切相关。...人类临床试验和几项动物实验表明,用某些糖醇(多元醇)替代蔗糖可以获得有希望的临床结果。在糖醇中,迄今为止效果最好的是木糖醇,它是一种含有五个碳原子的戊糖醇。含有木糖醇的口香糖已被证明是针对龋病活跃年龄组和高风险人群的强大工具。需要更多的研究来评估木糖醇与山梨糖醇、异麦芽酮糖、麦芽糖醇、其他糖醇和强力甜味剂混合物预防口腔菌斑疾病的能力。尽管尚未对碳水化合物甜味剂与牙周病之间的关系进行彻底的临床试验,但现有数据表明,饮食中的多元醇可能对牙周和牙龈炎症有一定的抑制效果。
Dental caries and periodontal disease are wide-spread oral illnesses whose etiology is intimately associated with the consumption of carbohydrate sweeteners. ...Human clinical trials and several animal experiments have shown promising clinical results obtained by replacing sucrose with certain sugar alcohols (polyols). Among the sugar alcohols, the best results so far have been obtained with xylitol, which is chemically a pentitol containing five carbon atoms. Chewing gums containing xylitol have been shown to be strong instruments against caries in caries-active age-groups and in high-risk subjects. More research is needed to assess the ability of mixtures of xylitol with sorbitol, palatinit, maltitol, other sugar alcohols, and intense sweeteners to prevent oral plaque diseases. Although thorough clinical trials on the relationship between carbohydrate sweeteners and periodontal diseases have not been performed, the available data indicate that dietary polyols may have a restricted dampening effect on periodontal and gingival inflammations.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
  • 解毒与急救
/SRP:/ 紧急急救:确保已经进行了充分的中和。如果患者停止呼吸,请开始人工呼吸,最好使用需求阀复苏器、袋阀面罩装置或口袋面罩,按训练操作。如有必要,执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果发生呕吐,让患者前倾或置于左侧(如果可能的话,头部向下)以保持呼吸道畅通,防止吸入。保持患者安静,维持正常体温。寻求医疗帮助。 /高醇(大于3个碳原子)及相关化合物/
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand-valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR as necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Higher alcohols (>3 carbons) and related compounds/
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
麦芽糖醇在血液中引起的化学变化与健康人和包括糖尿病在内的几种疾病患者中由葡萄糖引起的变化进行了比较。在给予健康受试者葡萄糖(12.5、25或50克)或麦芽糖醇(50克)后,测定了他们的血糖水平。根据葡萄糖吸收曲线,口服给药的麦芽糖醇中有38%通过肠道吸收,但麦芽糖醇的吸收比葡萄糖的吸收延迟。
Chemical changes in the blood induced by maltitol were compared with those induced by glucose in both healthy people and patients with several disorders, including diabetes mellitus. Blood glucose levels of healthy subjects were determined after the administration of glucose (12.5, 25, or 50 g) or maltitol (50 g). Based on the glucose absorption curve, 38% of the maltitol that was orally administered was absorbed through the intestinal tract, but the absorption of maltitol was more delayed than that of glucose.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
新西兰兔的小肠片段被翻转并孵化在100 mM的底物(麦芽糖醇、蔗糖或葡萄糖)中。在不同的孵化时间(20、40或60分钟)后取出,测定肠片腔液的体积和肠片的干重。麦芽糖醇被水解,水解产物被翻转的囊袋吸收。在腔液中没有检测到麦芽糖醇。与葡萄糖或蔗糖孵化后相比,麦芽糖醇孵化后腔液中的葡萄糖浓度增加速率较慢。水解和吸收的速率随着孵化时间的延长而降低。
Pieces of New Zealand rabbit small intestine were everted and incubated with 100 mM substrate (maltitol, sucrose, or glucose). After removal at different times (20, 40, or 60 min.) of incubation, the volume of serosal fluid and the dry mass of the gut pieces were determined. Maltitol was hydrolyzed, and the hydrolysis products were absorbed by the everted sacs. No maltitol was detected in the serosal fluid. The serosal glucose concentration increased at a slower rate after incubation with maltitol than after incubation with glucose or sucrose. The rate of hydrolysis and absorption decreased with the longer time of incubation.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
在体外翻转小肠袋研究中,(14)C-U-麦芽糖醇的运输以空肠最高,其次是回肠和十二指肠。口服给药(14)C-U-麦芽糖醇24小时后,60%的放射性活性在大肠、盲肠和粪便中被检测到。5%通过尿液排出,1.2%在24小时内以二氧化碳形式呼出。当(14)C-U-麦芽糖醇静脉注射时,1、3和24小时内分别有超过35%、60%和85%的给药剂量通过尿液排出。
In an in vitro study of (14)C-U-maltitol in everted intestinal sacs, the highest transport of (14)C-maltitol was displayed in the jejunum, followed by the ileum and duodenum. Twenty-four hr after oral administration of (14)C-U-maltitol, 60% of the radioactivity was detected in the cecum, large intestine, and feces. Five percent was excreted in the urine and 1.2% was expired as CO2 within 24 hr. When (14)C-U-maltitol was injected i.v., over 35, 60, and 85% of the administered dose was excreted in the urine within 1, 3, and 24 hr, respectively.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
两只雄性比格犬通过胃管给予麦芽糖醇-U-(14)C(51.2微居里)。在给药后32小时内收集血液样本。血浆中放射性标记物的峰值浓度在麦芽糖醇给药后2小时出现(304和263微克/毫升,以两只犬的麦芽糖醇当量表示)。48小时后尿液中的放射性活性占给药剂量的7.8%和3.8%。
Two male beagle dogs were given maltitol-U-(14)C (51.2 uCi) by stomach tube. Blood samples were collected until 32 hr after dosing. The peak radiolabel concentration in plasma was 2 hr after maltitol administration (304 and 263 ug/mL, expressed as maltitol equivalent in the 2 dogs). The radioactivity present in the urine after 48 hr was 7.8 and 3.8% of the administered dose in the 2 animals.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • TSCA:
    Yes
  • 安全说明:
    S24/25
  • WGK Germany:
    3
  • 海关编码:
    2932999099
  • RTECS号:
    LZ4394000
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    干燥、通风且低温保存

SDS

SDS:7af8fa6b1f03d8b0a23c6f16cf39cb76
查看

模块 1. 化学品
1.1 产品标识符
: Maltitol
产品名称
1.2 鉴别的其他方法
4-O-α-Glucopyranosyl-D-sorbitol
1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
仅用于研发。不作为药品、家庭或其它用途。

模块 2. 危险性概述
2.1 GHS-分类
根据全球协调系统(GHS)的规定,不是危险物质或混合物。
2.3 其它危害物 - 无

模块 3. 成分/组成信息
3.1 物 质
: 4-O-α-Glucopyranosyl-D-sorbitol
别名
: C12H24O11
分子式
: 344.31 g/mol
分子量


模块 4. 急救措施
4.1 必要的急救措施描述
吸入
如果吸入,请将患者移到新鲜空气处。 如呼吸停止,进行人工呼吸。
皮肤接触
用肥皂和大量的水冲洗。
眼睛接触
用水冲洗眼睛作为预防措施。
食入
切勿给失去知觉者通过口喂任何东西。 用水漱口。
4.2 主要症状和影响,急性和迟发效应
4.3 及时的医疗处理和所需的特殊处理的说明和指示
无数据资料

模块 5. 消防措施
5.1 灭火介质
灭火方法及灭火剂
用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
5.2 源于此物质或混合物的特别的危害
碳氧化物
5.3 给消防员的建议
如必要的话,戴自给式呼吸器去救火。
5.4 进一步信息
无数据资料

模块 6. 泄露应急处理
6.1 作业人员防护措施、防护装备和应急处置程序
避免粉尘生成。 避免吸入蒸气、烟雾或气体。
6.2 环境保护措施
不要让产品进入下水道。
6.3 泄漏化学品的收容、清除方法及所使用的处置材料
扫掉和铲掉。 放入合适的封闭的容器中待处理。
6.4 参考其他部分
丢弃处理请参阅第13节。

模块 7. 操作处置与储存
7.1 安全操作的注意事项
在有粉尘生成的地方,提供合适的排风设备。
7.2 安全储存的条件,包括任何不兼容性
贮存在阴凉处。 使容器保持密闭,储存在干燥通风处。
建议的贮存温度: 2 - 8 °C
7.3 特定用途
无数据资料

模块 8. 接触控制和个体防护
8.1 容许浓度
最高容许浓度
没有已知的国家规定的暴露极限。
8.2 暴露控制
适当的技术控制
常规的工业卫生操作。
个体防护设备
眼/面保护
请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。
皮肤保护
所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
戴手套取 手套在使用前必须受检查。
请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
身体保护
根据危险物质的类型,浓度和量,以及特定的工作场所选择身体保护措施。,
防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
呼吸系统防护
不需要保护呼吸。如需防护粉尘损害,请使用N95型(US)或P1型(EN 143)防尘面具。
呼吸器使用经过测试并通过政府标准如NIOSH(US)或CEN(EU)的呼吸器和零件。

模块 9. 理化特性
9.1 基本的理化特性的信息
a) 外观与性状
形状: 粉末
颜色: 白色
b) 气味
无数据资料
c) 气味阈值
无数据资料
d) pH值
无数据资料
e) 熔点/凝固点
熔点/凝固点: 149 - 152 °C
f) 沸点、初沸点和沸程
无数据资料
g) 闪点
无数据资料
h) 蒸发速率
无数据资料
i) 易燃性(固体,气体)
无数据资料
j) 高的/低的燃烧性或爆炸性限度 无数据资料
k) 蒸气压
无数据资料
l) 蒸汽密度
无数据资料
m) 密度/相对密度
无数据资料
n) 水溶性
50 g/l
o) n-辛醇/水分配系数
无数据资料
p) 自燃温度
无数据资料
q) 分解温度
无数据资料
r) 粘度
无数据资料

模块 10. 稳定性和反应活性
10.1 反应性
无数据资料
10.2 稳定性
无数据资料
10.3 危险反应
无数据资料
10.4 应避免的条件
无数据资料
10.5 不相容的物质
强氧化剂
10.6 危险的分解产物
其它分解产物 - 无数据资料

模块 11. 毒理学资料
11.1 毒理学影响的信息
急性毒性
无数据资料
皮肤刺激或腐蚀
无数据资料
眼睛刺激或腐蚀
无数据资料
呼吸道或皮肤过敏
无数据资料
生殖细胞致突变性
无数据资料
致癌性
IARC:
此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
生殖毒性
生殖毒性 - 兔子 - 经口
对生殖的影响:胚胎植入后死亡率(例如总着床胚胎数中死亡和/或被再吸收的胚胎数)。
对生殖的影响:流产。
特异性靶器官系统毒性(一次接触)
无数据资料
特异性靶器官系统毒性(反复接触)
无数据资料
吸入危险
无数据资料
潜在的健康影响
吸入 吸入可能有害。 可能引起呼吸道刺激。
摄入 如服入是有害的。
皮肤 通过皮肤吸收可能有害。 可能引起皮肤刺激。
眼睛 可能引起眼睛刺激。
附加说明
化学物质毒性作用登记: 无数据资料

模块 12. 生态学资料
12.1 生态毒性
无数据资料
12.2 持久性和降解性
无数据资料
12.3 潜在的生物累积性
无数据资料
12.4 土壤中的迁移性
无数据资料
12.5 PBT 和 vPvB的结果评价
无数据资料
12.6 其它不良影响
无数据资料

模块 13. 废弃处置
13.1 废物处理方法
产品
将剩余的和不可回收的溶液交给有许可证的公司处理。
受污染的容器和包装
按未用产品处置。

模块 14. 运输信息
14.1 联合国危险货物编号
欧洲陆运危规: - 国际海运危规: - 国际空运危规: -
14.2 联合国运输名称
欧洲陆运危规: 非危险货物
国际海运危规: 非危险货物
国际空运危规: 非危险货物
14.3 运输危险类别
欧洲陆运危规: - 国际海运危规: - 国际空运危规: -
14.4 包裹组
欧洲陆运危规: - 国际海运危规: - 国际空运危规: -
14.5 环境危险
欧洲陆运危规: 否 国际海运危规 国际空运危规: 否
海洋污染物(是/否): 否
14.6 对使用者的特别提醒
无数据资料


模块 15 - 法规信息
N/A


模块16 - 其他信息
N/A

制备方法与用途

鉴别试验

  • 溶解性:易溶于水,微溶于乙醇 (OT-42)。
  • 熔点:148~151℃。
  • 薄层色谱试验:用涂有0.25mm色谱级硅胶的色谱板。取D-麦芽糖醇标准样0.50mg,溶于20ml水中作为参比液。将适量试样溶于水中,使该试样液中约含麦芽糖醇2.5mg/ml(以干基计)。操作如下:取参比液和试样液各2ml点于色谱板底部,用由70份正丁醇、20份醋酸乙酯和10份水配制的展开剂展开至17cm。从展开室中取出色谱板,标出溶剂前沿位置后使溶剂蒸发。再用0.2% (W/V)偏高碘酸钠液喷色板,并在空气中干燥15分钟。最后用溶于丙酮和冰醋酸(4:1)混合液的2% (W/V) 4, 4-四甲基二氨基-二苯甲烷溶液喷雾。所得试样液主色斑的R值应与参比液相似。

含量分析
准确称取约1.5g试样,放入100ml容量瓶中,用重蒸蒸馏水定容并搅拌1小时后,经0.45μm微孔烧结漏斗过滤。取滤液进行分析。

用途

  • 低热值甜味剂:适用于糖尿病和肥胖症患者。
  • 良好的保湿作用:可用于糕点、饼干、面包、雪糕、冰棍、饮料、糖果及酱菜,按生产需要适量使用。
  • 防龋齿甜味剂:可作为蜜饯等保香剂、粘稠剂、保湿剂以及米果的品质改良剂。
  • 改善糖精钠风味:具有湿润、稳定和组织改进等功能。

生产方法
麦芽糖醇一般由麦芽糖高压氢化制得: [ \text{C}{12}\text{H}{22}\text{O}{11} + 2\text{H}2[\text{Ni}] → \text{C}{11}\text{H}{24}\text{O}_{11} ] 在30%的麦芽糖水溶液中加入10%的骨架镍催化剂,在4~12MPa和100~150℃下搅拌加氢。加氢结束后用活性炭脱色,再经阳离子树脂交换除去镍离子。将糖醇液浓缩至80%,加入1%的无水结晶麦芽糖醇,在连续搅拌下3天内逐步冷却至20℃,离心分离结晶并用少量水洗涤。产品纯度可达99%。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    麦芽糖醇 生成 Maltitol-nonaacetat
    参考文献:
    名称:
    SHINOHARA, YASURO;MORI, MASAMI;TEJIMA, SETSUZO, YAKUGAKU DZASSI, 108,(1988) N 11, S. 1046-1055
    摘要:
    DOI:
  • 作为产物:
    描述:
    麦芽糖1-甲基吡咯烷 、 Ru-MACHO-BH 、 氢气 作用下, 以 乙醇 为溶剂, 150.0 ℃ 、5.0 MPa 条件下, 反应 6.0h, 以76%的产率得到麦芽糖醇
    参考文献:
    名称:
    Ru-MACHO-BH 催化的糖的高效选择性加氢:糖醇的实用合成
    摘要:
    通过使用均相催化剂的选择性氢化实现了糖醇的高效合成。PN H P-钌催化剂Ru-MACHO-BH以极高的反应性和选择性促进氢化。该反应可应用于各种单糖和双糖,并已成功在几十克的规模上运行。
    DOI:
    10.1021/acs.oprd.2c00047
  • 作为试剂:
    描述:
    Erythritol麦芽糖醇麦芽糖醇 作用下, 反应 12.17h, 以yielding 107 g of powder (eutectic crystalline erythritol/maltitol)的产率得到Erythritol Maltitol
    参考文献:
    名称:
    Method of manufacturing an eutectic crystalline sugar alcohol
    摘要:
    一种制造共熔晶体山梨醇/麦芽醇的方法,其通过差示扫描量热法得到单一熔点。该方法包括将含有两种或两种以上糖醇的液态组合物以预定比例与含有相同两种或两种以上糖醇晶体的粉末以基本相同的使用比例混合,然后进行揉捏和老化处理。
    公开号:
    US20110086924A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL THYROMIMETICS<br/>[FR] NOUVEAUX THYROMIMÉTIQUES
    申请人:AUTOBAHN THERAPEUTICS INC
    公开号:WO2021108549A1
    公开(公告)日:2021-06-03
    Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, X1, X2, Y1, and Y2 are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.
    提供具有Formula (I)结构或其药学上可接受的异构体、拉克酸盐、水合物、溶剂化合物、同位素或盐的化合物,其中R1、R2、X1、X2、Y1和Y2如本文所定义。这些化合物作为甲状腺类似物发挥作用,并可用于治疗神经退行性疾病和纤维化疾病等疾病。还提供含有这些化合物的药物组合物,以及它们的使用和制备方法。
  • [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROTHROMBOSIS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE L'ATHÉROTROMBOSE
    申请人:KANDULA MAHESH
    公开号:WO2013024376A1
    公开(公告)日:2013-02-21
    The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration- transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may foe used to treatment of vascular disorders or conditions such as thrombotic cerebrovascular or cardiovascular disease or its associated complications.
    本公开提供公式I的化合物或其药用可接受的盐,以及其多晶型、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以用于口服、经皮、经粘膜、糖浆、局部、延长释放、持续释放或注射的给药。这种组合物可用于治疗血管疾病或病况,如血栓性脑血管或心血管疾病或其相关并发症。
  • [EN] DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE<br/>[FR] DÉRIVÉS DE TOXINES D'AMANITES ET LEUR CONJUGAISON À UNE MOLÉCULE DE LIAISON CELLULAIRE
    申请人:HANGZHOU DAC BIOTECH CO LTD
    公开号:WO2017046658A1
    公开(公告)日:2017-03-23
    Derivatives of Amernita toxins of Formula (I), wherein, formula (a) R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, X, L, m, n and Q are defined herein. The preparation of the derivatives. The therapeutic use of the derivatives in the targeted treatment of cancers, autoimmune disorders, and infectious diseases.
    Amernita毒素的衍生物的化学式(I),其中,化学式(a)中的R 1、R 2、R 3、R 4、R 5、R 6、R 7、R 8、R 9、R 10、X、L、m、n和Q在此处被定义。这些衍生物的制备。这些衍生物在靶向治疗癌症、自身免疫性疾病和传染病中的治疗用途。
  • [EN] A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS<br/>[FR] CONJUGUÉ D'UN AGENT CYTOTOXIQUE À UNE MOLÉCULE DE LIAISON CELLULAIRE AVEC DES LIEURS RAMIFIÉS
    申请人:HANGZHOU DAC BIOTECH CO LTD
    公开号:WO2020257998A1
    公开(公告)日:2020-12-30
    Provided is a conjugation of cytotoxic drug to a cell-binding molecule with a side-chain linker. It provides side-chain linkage methods of making a conjugate of a cytotoxic molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and immunological disorders.
    提供了一种将细胞毒性药物与一个侧链连接分子结合的共轭物。它提供了制备细胞毒性分子与细胞结合配体的共轭物的侧链连接方法,以及在靶向治疗癌症、感染和免疫性疾病中使用该共轭物的方法。
  • [EN] CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES<br/>[FR] DÉRIVÉ DE DIMÈRE DE PYRROLOBENZODIAZÉPINE RÉTICULÉ (PBD) ET SES CONJUGUÉS
    申请人:HANGZHOU DAC BIOTECH CO LTD
    公开号:WO2020006722A1
    公开(公告)日:2020-01-09
    A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.
    一种新型的交联细胞毒剂,吡咯苯并二氮杂环二聚体(PBD)衍生物,以及它们与细胞结合分子的结合物,一种制备这些结合物的方法以及这些结合物的治疗用途。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台